Deccan health care Limited has announced the resignation of two Non-Executive Independent Directors from its Board, effective March 2026. The company informed BSE Limited about these corporate governance changes in compliance with SEBI Listing Regulations.

Director Resignations and Timeline

Two key independent directors have stepped down from their positions within a day of each other. The resignations represent significant changes to the company's board composition.

Reasons for Resignation

Both directors cited personal reasons for their departure from the Board. Ms. Samhitha Kandlakunta's resignation letter dated 9th March 2026 stated her decision was due to relocation overseas for career progression. She emphasized that her decision was entirely personal with no material concerns regarding fellow directors, management, or the company's governance practices.

Ms. Karishma Patel, in her resignation letter dated 10th March 2026, cited increased workload in personal commitments and other work responsibilities as the reason for her inability to continue as Independent Director. She confirmed there were no other material reasons beyond those mentioned for her resignation.

Regulatory Compliance and Disclosures

The company has fulfilled all regulatory requirements under SEBI Listing Regulations. Key compliance aspects include:

Board Acknowledgment

The Board of Directors expressed appreciation for both directors' valuable contribution and support during their tenure as Non-Executive Independent Directors. The company acknowledged their professional service and cooperation throughout their association with Deccan Health Care Limited.

The resignations were processed in accordance with SEBI Circular No. SEBI/HO/CFD/CFDPoD-1/P/CIR/2023/123 dated 13th July 2023, with all required disclosures provided in the regulatory filing. The company has requested BSE to take the resignations on record and will arrange necessary filings with the Registrar of Companies.

Deccan Health Care Limited has announced strong financial results for the quarter and nine months ended December 31, 2025, demonstrating robust growth across key performance metrics. The company's sustained operational momentum and strategic execution have translated into significant improvements in revenue, profitability, and earnings per share.

Quarterly Financial Performance

The company's standalone performance for Q3FY26 showed remarkable improvement across all major financial parameters:

The exceptional growth in profitability metrics reflects the company's focus on operational efficiency, cost optimization initiatives, and improved production efficiencies. The revenue expansion was driven by market expansion efforts and stronger contribution from higher-margin product categories.

Nine-Month Performance Highlights

For the nine-month period ended December 31, 2025, Deccan Health Care maintained strong momentum with consistent growth across financial metrics:

The nine-month results demonstrate the company's ability to sustain growth momentum throughout the financial year, with revenue growth of 27% and nearly doubling of profit after tax.

Strategic Developments and Market Expansion

Deccan Health Care achieved significant milestones in its international expansion strategy during the quarter. The company successfully completed its UAE product registration process, marking a crucial step in its export readiness initiatives. The first export consignment is expected to be shipped in the first quarter of the next financial year, opening new revenue streams for the company.

Key strategic priorities during the quarter included:

• Expansion into new markets while deepening penetration in existing geographies
• Cost optimization initiatives across operations
• Strengthening presence in higher-margin R&D-driven product categories
• Improving production efficiency and yield across manufacturing facilities

Product Portfolio and Innovation

The company's nutraceutical weight wellness lifestyle range, launched in the previous quarter, has received encouraging market response and growing customer traction. This positive reception reinforces confidence in the long-term potential of this product category and demonstrates the company's ability to innovate and capture emerging market opportunities.

Consolidated Performance

On a consolidated basis, the company showed steady quarter-on-quarter improvement with PAT of ₹100.25 lakhs in Q3FY26, representing a 10% increase from ₹91.40 lakhs in Q2FY26. Basic EPS on consolidated basis reached ₹0.41, up 11% from ₹0.37 in the previous quarter.

For the nine-month consolidated performance:

The results reflect a company that is strengthening its profitability profile while maintaining disciplined execution, export readiness, and innovation-led expansion. Deccan Health Care Limited remains focused on sustainable long-term value creation for all stakeholders through structured consolidation and disciplined growth strategies.